Navigation Links
Savient Pharmaceuticals to Hold Second Quarter 2011 Financial Results Conference Call on Thursday, August 4, 2011
Date:7/20/2011

EAST BRUNSWICK, N.J., July 20, 2011 /PRNewswire/ -- Savient Pharmaceuticals, Inc. (NASDAQ: SVNT) announced today that the Company will release financial results for the second quarter 2011 prior to the open of the market on Thursday, August 4, 2011.

John H. Johnson, Chief Executive Officer and President, and David Gionco, Group Vice President and Chief Financial Officer, will host an investment community conference call beginning at 9:00 a.m. Eastern Time on August 4, 2011, to discuss these results and to answer questions.

To participate by telephone, please dial 877-278-8171 (Domestic) or 574-941-7303 (International). The conference ID number is 84217509. The live and archived webcast can be accessed on the investor relations section of the Savient website at www.savient.com. Please log on to Savient's website fifteen minutes prior to the start of the call to ensure adequate time for any downloads that may be necessary.

A telephone replay will be available from 12:00 p.m. Eastern Time on August 4, 2011, through 12:00 a.m. Eastern Time on August 14, 2011, by dialing 855-859-2056 (Domestic) or 404-537-3406 (International) and entering conference ID number 84217509.

About Savient Pharmaceuticals, Inc.

Savient Pharmaceuticals, Inc. is a specialty biopharmaceutical company focused on developing and commercializing KRYSTEXXA® (pegloticase) for the treatment of chronic gout in adult patients refractory to conventional therapy. Savient has exclusively licensed worldwide rights to the technology related to KRYSTEXXA and its uses from Duke University ("Duke") and Mountain View Pharmaceuticals, Inc. ("MVP").  Duke developed the recombinant uricase enzyme and MVP developed the PEGylation technology used in the manufacture of KRYSTEXXA. MVP and Duke have been granted U.S. and foreign patents disclosing and claiming the licensed technology and, in addition, Savient owns or co-owns U.S. and foreign patents and patent applications, which collectively form a broad portfolio of patents covering the composition, manufacture and methods of use and administration of KRYSTEXXA.  Savient also manufactures and supplies Oxandrin® (oxandrolone tablets, USP) CIII in the U.S. For more information, please visit the Company's website at www.savient.com.

SVNT-I


'/>"/>
SOURCE Savient Pharmaceuticals, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. Savient Announces FDAs Advisory Panel to Review Pegloticase for Treatment-Failure Gout Patients
2. Savient Provides Update on Pegloticase BLA
3. Savient Pharmaceuticals Announces Proposed Public Offering of Common Stock
4. Savient Pharmaceuticals Prices Underwritten Offering of Common Stock
5. Savient Pharmaceuticals Announces Closing of Public Offering and Exercise of Over-Allotment Option
6. Savient Pharmaceuticals Reports Third Quarter 2009 Financial Results
7. Savient Provides Update on KRYSTEXXA(TM) BLA Resubmission Activities
8. Savient Pharmaceuticals To Hold Fourth Quarter And Year-End 2009 Results Conference Call On Friday, February 26, 2010
9. Savient Pharmaceuticals Reports Fourth Quarter and Year-End 2009 Financial Results
10. Savient Resubmits Biologics License Application for KRYSTEXXA(TM) (pegloticase) for the Treatment of Chronic Gout in Patients Refractory to Conventional Therapy
11. Savient Pharmaceuticals To Hold First Quarter 2010 Results
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/11/2016)... February 11, 2016 Jeffrey Zucker ... Clinical Trials, will present at this year,s Summit for Clinical ... Regency in Miami, FL. Zucker will ... optimize study execution, supporting SCOPE,s "Improving Site Study Activation and ... on Thursday, Feb. 25 at 11:05 a.m. ...
(Date:2/11/2016)... 2016  Community pharmacists can help improve medication adherence ... through a custom-built medication synchronization program, Cardinal Health MedSync ... at Schieber Family Pharmacy in ... of patients enrolled in this medication synchronization program, which ... for the patient, and it,s a win for us ...
(Date:2/11/2016)... , Feb. 11, 2016  M3 Biotechnology Inc., spurred by a major "team investment" by ... brother, Michael, has completed an oversubscribed Series A-Round, according to CEO Leen Kawas , PhD. ... ... ... ...
Breaking Medicine Technology:
(Date:2/12/2016)... , ... February 12, 2016 , ... Yisrayl Hawkins, Pastor ... article this week that uncovers what he says are the real facts surrounding all ... the Bible from parents and Sunday school teachers, and Yisrayl says there is more ...
(Date:2/12/2016)... (PRWEB) , ... February 12, 2016 , ... Dignity Health ... General Hospital Emergency Room –Mesa. The new facility is licensed under Dignity ... , “Dr. Bingham is an excellent leader and will ensure our new freestanding emergency ...
(Date:2/11/2016)... ... 11, 2016 , ... SPH Analytics announced today that ... health solutions, MDinsight® and IndiGO®, for its primary care clinicians. The 3-year partnership ... the contract were not disclosed. , As the healthcare market moves towards quality-based ...
(Date:2/11/2016)... Tampa, FL (PRWEB) , ... February 11, 2016 , ... ... Tampa Bay Lightning take on the St. Louis Blues at the Amalie Arena. The ... only portable, inflatable, walk-through heart exhibit, the MEGA Heart, prior to the game. The ...
(Date:2/11/2016)... ... February 11, 2016 , ... ... ranked among the top five firms in the “2015/2016 Best in KLAS: Software ... and Staffing. KLAS is a research and insights firm on a global mission ...
Breaking Medicine News(10 mins):